What you should know about your lung cancer biomarker testing results report

Biomarkers are measurable characteristics of your cells that can provide information about your non-small cell lung cancer (NSCLC). Certain biomarkers are “drivers” that cause cancer to grow and spread.

Testing to see if you have these biomarkers allows your healthcare team to make a personalized treatment plan. Comprehensive biomarker testing in NSCLC is recommended. It tests for all recommended biomarkers based on clinical guidelines to help healthcare professionals understand more about your specific type of cancer.

Your biomarker status appears on your biomarker testing report. The report lists all the biomarkers for which you were tested and which, if any, were found.

Your healthcare team will explain your test results

Your biomarker status appears on your biomarker testing report. The report lists all the biomarkers for which you were tested and which, if any, were found.

Your results may affect your treatment options

Most reports name the FDA-approved therapy, or therapies, that may be effective based on your biomarkers. These could include a targeted therapy, immunotherapy, or chemotherapy.

You can get a copy of your test results report

Ask your doctor or nurse for a printed and electronic copy of your report. You can use it when you talk to others about your results or if you are seeking a second opinion from another doctor.

You can call the doctor with questions

If you have additional questions about your results, consider calling the pathologist, the doctor who analyzed your results. Most reports include the pathologist’s name and contact information.

You can get support

Waiting for results can be stressful; contact LUNGevity’s peer-to-peer support coordinator at 312-407-6116.

Know your biomarkers. Know your options.

To learn more about biomarkers and to read stories by lung cancer patients and survivors who have experienced comprehensive biomarker testing, visit LUNGevity.org/NoOneMissed

No One Missed is brought to you by the LUNGevity Foundation and made possible with the support of AstraZeneca, Amgen, and Genentech, a member of the Roche Group.

©2021 LUNGevity